Biocon Biologics Draws FDA OAI Classification, Nectar Gets Untitled Letter

In the latest FDA blow to Biocon Biologics, a July inspection of its insulin production facility in Johor, Malaysia, has been classified by the agency as “Official Action Indicated” (OAI), the most serious inspection classification and one step short of a warning letter or other enforcement action.
Source: Drug Industry Daily